文献速递前列腺癌

前列腺癌患者淋巴结转移预测机器学习模型的开发与外部验证

Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-03-01

基于两家学术机构1990至2020年接受手术及盆腔淋巴结清扫的前列腺癌患者回顾性数据,在一家机构20267例中训练三种模型(含XGBoost),在另一家机构1322例中外部验证。XGBoost外部验证AUC优于Roach公式0.08、MSKCC列线图0.05、Briganti列线图0.03,校准与决策曲线净获益亦更优。

要点

  • XGBoost外部验证AUC较Roach公式高0.08(95%CI 0.042-0.12),较MSKCC列线图高0.05(95%CI 0.016-0.070)。
  • XGBoost外部验证AUC较Briganti列线图高0.03(95%CI 0.0092-0.051),所有比较p<0.05。
  • XGBoost在相关临床阈值范围内决策曲线净获益更优,校准更好。

核心结论

  • 综合各项性能指标,使用标准临床病理变量的机器学习在预测淋巴结受累方面优于传统工具。

研究设计与样本

  • 回顾性数据,患者于1990至2020年在两家学术机构接受手术和盆腔淋巴结清扫。
  • 在一家机构20267例数据上训练两种逻辑回归模型和一种梯度提升树模型(XGBoost),输入年龄、前列腺特异性抗原(PSA)水平、临床T分期、阳性穿刺针百分比和Gleason评分。
  • 在另一家机构1322例数据上进行外部验证,并与传统模型比较。

主要发现

  • 整体淋巴结受累2563例(11.9%),验证数据集119例(9%)。
  • XGBoost在所有模型中表现最佳。
  • 外部验证中,XGBoost的AUC较Roach公式高0.08(95%CI 0.042-0.12),较MSKCC列线图高0.05(95%CI 0.016-0.070),较Briganti列线图高0.03(95%CI 0.0092-0.051;所有p<0.05)。
  • XGBoost在相关临床阈值范围内决策曲线净获益更优,校准更好。

关键数值与推荐

  • XGBoost外部验证AUC较Roach公式高0.08(95%CI 0.042-0.12)。
  • XGBoost外部验证AUC较MSKCC列线图高0.05(95%CI 0.016-0.070)。
  • XGBoost外部验证AUC较Briganti列线图高0.03(95%CI 0.0092-0.051;所有p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要局限性为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pelvic lymph node dissection (PLND) is the gold standard for diagnosis of lymph node involvement (LNI) in patients with prostate cancer. The Roach formula, Memorial Sloan Kettering Cancer Center (MSKCC) calculator, and Briganti 2012 nomogram are elegant and simple traditional tools used to estimate the risk of LNI and select patients for PLND. OBJECTIVE: To determine whether machine learning (ML) can improve patient selection and outperform currently available tools for predicting LNI using similar readily available clinicopathologic variables. DESIGN, SETTING, AND PARTICIPANTS: Retrospective data for patients treated with surgery and PLND between 1990 and 2020 in two academic institutions were used. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We trained three models (two logistic regression models and one gradient-boosted trees-based model [XGBoost]) on data provided from one institution (n = 20267) with age, prostate-specific antigen (PSA) levels, clinical T stage, percentage positive cores, and Gleason scores as inputs. We externally validated these models using data from another institution (n = 1322) and compared their performance to that of the traditional models using the area under the receiver operating characteristic curve (AUC), calibration, and decision curve analysis (DCA). RESULTS AND LIMITATIONS: LNI was present in 2563 patients (11.9%) overall, and in 119 patients (9%) in the validation data set. XGBoost had the best performance among all the models. On external validation, its AUC outperformed that of the Roach formula by 0.08 (95% confidence interval [CI] 0.042-0.12), the MSKCC nomogram by 0.05 (95% CI 0.016-0.070), and the Briganti nomogram by 0.03 (95% CI 0.0092-0.051; all p < 0.05). It also had better calibration and clinical utility in terms of net benefit on DCA across relevant clinical thresholds. The main limitation of the study is its retrospective design. CONCLUSIONS: Taking all measures of performance together, ML using standard clinicopathologic variables outperforms traditional tools in predicting LNI. PATIENT SUMMARY: Determining the risk of cancer spread to the lymph nodes in patients with prostate cancer allows surgeons to perform lymph node dissection only in patients who need it and avoid the side effects of the procedure in those who do not. In this study, we used machine learning to develop a new calculator to predict the risk of lymph node involvement that outperformed traditional tools currently used by oncologists.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sabbagh A, Washington SL, Tilki D, et al. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023. PMID: 36868922. doi:10.1016/j.euo.2023.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。